Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018)
Arvinas (ARVN) recorded quarterly Preferred Stock Liabilities of $81.1 million in Q3 2018, up 94.35% quarter-over-quarter from $41.7 million in Q4 2017, and up 429.86% on a YoY basis from $15.3 million in Q3 2017.
Arvinas (ARVN) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Arvinas' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $81.1 million for Q3 2018.
- In Q3 2018, Preferred Stock Liabilities rose 429.86% year-over-year to $81.1 million; the TTM figure through Sep 2018 stood at $81.1 million (up 429.86% YoY), while the FY2017 annual figure was $41.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $81.1 million for Q3 2018 at Arvinas, up from $41.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $81.1 million in Q3 2018 to a low of $15.3 million in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 81.07 Mn |
| Dec 31, 2017 | 41.71 Mn |
| Sep 30, 2017 | 15.30 Mn |